从指南推荐、预后改善和药物经济学浅谈血管紧张素转换酶抑制剂与血管紧张素受体拮抗剂的异同

来源 :中华高血压杂志 | 被引量 : 0次 | 上传用户:zxzcmj
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
高血压是最常见的心血管病,严重危害人类健康,良好的血压控制,对冠状动脉性心脏病(冠心病)、脑卒中等心血管病的一级、二级预防均具有重要意义。血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitors,ACEI)是一线降压药物,具有良好的降压和心血管保护作用,它的发明开创了心血管病治疗的里程碑。随后问世的血管紧张素受体拮抗剂(angiotensin receptor blockers,ARB),与ACEI同 Hypertension is the most common cardiovascular disease, which seriously endangers human health and has good blood pressure control. It is of great importance to primary and secondary prevention of cardiovascular diseases such as coronary heart disease (CHD) and stroke. Angiotensin converting enzyme inhibitors (ACEIs) are first-line antihypertensive drugs with good antihypertensive and cardiovascular protective effects. Its invention has set a milestone in the treatment of cardiovascular diseases. Subsequently came out of angiotensin receptor blockers (ARB), ACEI with
其他文献
期刊
期刊